Gilead Sciences (GILD)
Gilead Sciences Revenues: 2.282B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
GILD Revenues Rankings
| Overall | 90th percentile | 401 of 4425 |
| Sector | 94th percentile | 28 of 470 in Healthcare |
| Industry | 98th percentile | 2 of 132 in Biotechnology |
GILD Revenues Range, Past 5 Years
| Minimum | 1.048B | Jun 2007 |
| Maximum | 2.282B | Mar 2012 |
| Average | 1.708B |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these GILD related companies
GILD News
$IDIX looks like the 12.5 17.5 spread is due 2 possible $6/share bump if $GILD settles on Hep. C drug...interesting
about 16 hours ago by johnkelly
about 16 hours ago by johnkelly
Brean Murray Sees Recent Upside in Idenix (IDIX) Related to Possible Gilead (GILD) Settlement in June
May 24, 5:14PM Street Insider
May 24, 5:14PM Street Insider
$GILD Gilead Sciences Inc: Strong Growth At An Unreasonably Low Price
http://stks.co/3vBM
about 8 days ago by FASTgraphs
about 8 days ago by FASTgraphs
$GILD Gilead Sciences (GILD): Report from the AGM http://stks.co/3sEw #corpgov
about 13 days ago by corpgovnet
about 13 days ago by corpgovnet
$GILD and thoer Truvada HiV prevention drug may get a boost on $OSUR unan. 17-0 fda panel review vote
about 14 days ago by QR_Winner
about 14 days ago by QR_Winner
$GILD..imo still an undervalued play here heading towards new 52 week high
about 15 days ago by ACE52WeekHigh
about 15 days ago by ACE52WeekHigh
Market Wrap Video + Additions to Watch List http://stks.co/3p31 including: $GPRN $VRTX $PBH $CNQR $INSP $CIEN $GILD
about 15 days ago by StockTiger
about 15 days ago by StockTiger
$GILD Panel member "I suggest (you name this) Quadzilla"
about 16 days ago by Lookatthesky
about 16 days ago by Lookatthesky
Gilead Sciences (GILD) Gets FDA Advisory Committee Support of Quad HIV-1 Treatment
May 11, 3:32PM Street Insider
May 11, 3:32PM Street Insider
FDA Advisory Committee Supports Approval of Gilead’s Once-Daily Quad Single Tablet Regimen for HIV
May 11, 3:31PM Business Wire
May 11, 3:31PM Business Wire
$GILD on top of Truvada, QUAD approval today could be worth $4Billion in revs. http://stks.co/3mj8
about 19 days ago by Lookatthesky
about 19 days ago by Lookatthesky
FDA Advisory Committee Supports Approval of Gilead’s Truvada® for Reducing the Risk of Acquiring HIV
May 10, 8:35PM Business Wire
May 10, 8:35PM Business Wire
FDA says Gilead's (GILD) HIV combo pill has 'generally acceptable' safety
May 09, 7:55AM Street Insider
May 09, 7:55AM Street Insider
Gilead (GILD) Begins Phase 3 Trial Evaluating GS-1101 for Lymphocytic Leukemia
May 01, 6:05PM Street Insider
May 01, 6:05PM Street Insider
Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment of Chronic Lymphocytic Leukemia
May 01, 6:00PM Business Wire
May 01, 6:00PM Business Wire
Gilead Sciences to Present at the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8
May 01, 4:30PM Business Wire
May 01, 4:30PM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GILD | 50.97 | +0.48 | +0.95% | 38.27B |
| GIL | 25.13 | +0.09 | +0.36% | 3.043B |
| GIII | 25.41 | +0.71 | +2.87% | 488.32M |
| GII | 38.61 | +0.18 | +0.47% | |
| GIGM | 1.15 | +0.00 | +0.00% | 63.64M |
| GIGA | 1.03 | +0.00 | +0.00% | 5.171M |
| GIB | 20.51 | +0.33 | +1.64% | 4.543B |
| GGP | 17.32 | +0.51 | +3.00% | |
| GGEM | 20.00 | -0.13 | -0.64% | |
| GGE | 16.35 | +0.20 | +1.27% |
